Clinical Trial Update: Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of oral lenvatinib in medullary and iodine-131 refractory, unresectable differentiated thyroid cancers; study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer
• Medullary Thyroid Cancer
• Thyroid Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Eisai Inc. | Conditions: Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-08-01